Cholecystokinin C-45T polymorphism and smoking cessation in women

What Was Tested

Researchers studied Cholecystokinin (CCK) in this randomized controlled trial publication.

In view of the effect of cholecystokinin (CCK) on dopaminergic neurons in the mesolimbic "reward" pathway of the brain, its gene has been a focus in studies of dopamine-related conditions and behaviors, including smoking.

The researchers assessed the association between the CCK C-45T polymorphism and smoking cessation among women who participated in a randomized clinical trial of d,l-fenfluramine conducted in the Seattle area in 1993-1994.

Who Took Part

The abstract describes 593 women taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Cholecystokinin (CCK) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Cholecystokinin (CCK) group a baseline to be compared against.

What Was Measured

The researchers assessed the association between the CCK C-45T polymorphism and smoking cessation among women who participated in a randomized clinical trial of d,l-fenfluramine conducted in the Seattle area in 1993-1994.

Topics PubMed links to this paper include Alleles, Body Mass Index, Cholecystokinin, Genotype, Polymerase Chain Reaction, Polymorphism, Genetic and Smoking.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Cholecystokinin (CCK) in 593 women.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2007 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.

More context: the Cholecystokinin (CCK) compound page, all human trials.